Drug Development

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Articles

Accelerated development of new preventives raises challenges for efficient CMC evaluation and production.


Modern Manufacturing Key to More Effective Vaccines

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

The high viscosity of highly concentrated monoclonal antibody formulations not only presents processing and storage difficulties, but also formulation and delivery challenges.

Delivering High-Concentration Protein Formulations

Devyn Smith, PhD, is chief operations officer and head of strategy of Sigilon Therapeutics.

Researchers at MIT have discovered a new set of compounds that do not elicit a foreign body response when implanted. These biomaterials permit the development of a new category of treatment with the ability to deliver therapeutics either at a constant rate or under programmable conditions by using implantable cells as protein factories.

Future Therapies Using Implanted Engineered Cells as Protein Factories

Daniela Neubert is liquid chromatography analyst at OFI Technologie & Innovation GmbH in Vienna.

Nicole Steiner-ReischÃ¼tz is coordinator at OFI Technologie & Innovation GmbH in Vienna.

Michael Pyerin is head of pharma, medical devices, and hygiene at OFI Technologie & Innovation GmbH in Vienna.

Michael WashÃ¼ttl is head of packaging at OFI Technologie & Innovation GmbH in Vienna.

Michael Krainz is project manager for packaging at OFI Technologie & Innovation GmbH in Vienna.

Chrysoula Kanakaki is GC chromatography analyst at OFI Technologie & Innovation GmbH in Vienna.

Research suggests that radiation can have a significant impact on the composition and rheology of hydroxyethyl cellulose-based medicinal gels.

Evaluating the Impact of Sterilization on Gel Formulations

The companies will co-develop and co-promote a CAR T cell therapy in the United States.

Celgene, bluebird bio Partner on CAR-T Therapy

Novartis’ Sandoz is seeking approval of its biosimilar referencing Johnson & Johnson’s Remicade (infliximab) for all of Remicade’s indications across gastroenterology, rheumatology, and dermatology.

Novartis Gets Positive EMA Opinion on Biosimilar to J&J’s Remicade

EMA has recommended approval of the biosimilar for the same indications as Roche’s Herceptin (trastuzumab).

Amgen, Allergan Score Positive EMA Opinion on Biosimilar to Roche’s Herceptin

Major countries will be ranked based on the potential for biopharma market growth, innovation, and competitiveness. 

bioLIVE to Launch Global Biopharma Country Ranking

MedPharm has received a multi-million dollar investment by Ampersand Capital Partners to diversify its service offering and regional coverage.

MedPharm Receives Investment from Ampersand Capital Partners

Hitachi will manufacture regenerative medicines developed by Daiichi Sankyo and SanBio Group.

Formulation and Drug Delivery